Find policies, billing codes, payers, states, and providers
Topical Acne-Non-Retinoid Products
Customize your policy alerts
Sign up for Cigna Policy IP0166 alerts
Get alerted when Policy IP0166 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and coverage criteria for topical non‑retinoid acne products (e.g., clindamycin, minocycline, combination benzoyl peroxide products) for Cigna‑administered health plans.
Removed Dapsone products (Aczone) medical necessity criteria from this policy.
Employer Preferred Product table: Removed Onexton preferred product requirements.
No criteria changes noted for recent reviews leading to effective date 08/15/2026.
Coverage Criteria for Topical Non‑Retinoid Acne Products
Clindamycin-containing products (Clindagel) — Employer Plans
Covered when ALL of the following are met:
Employer plan specific wording.
Amzeeq (minocycline 4% foam) — Employer Plans
Covered when ALL of the following are met:
Employer plan specific wording.
Combination clindamycin/benzoyl peroxide products (Acanya, BenzaClin, clindamycin/benzoyl formulations, Neuac, Onexton) — Employer Plans
Covered when specified combinations of prior trials or failures are documented:
Employer plan wording.
Employer plan wording.
Employer plan wording.
Employer plan wording.
Clindamycin/benzoyl peroxide 1.2%/3.75% gel — Individual and Family Plans
Covered when ONE of the following alternative trials is documented:
Individual and Family plan wording.
The medical necessity criteria for dapsone topical products (Aczone) have been removed from this policy. This change is documented in the Revision Details as “Removed Dapsone products (Aczone) medical necessity criteria from this policy,” with the removal recorded 09/19/2024 and an effective date of 01/01/2025. Providers should no longer reference this policy for coverage criteria specific to Aczone.
Claims for services that are billed for conditions or diagnoses not covered under this Coverage Policy will be denied as not covered. When submitting claims, providers must use the most appropriate diagnosis and procedure codes as of the date of submission; claims submitted without covered code(s) under this policy are subject to denial.
Provider Actions, Prior Authorization and Documentation Requirements
Obtain prior authorization when coverage criteria are met for branded topical non‑retinoids
Prior authorization is required when coverage is available and the medical necessity criteria in this policy are met for branded topical non‑retinoid acne products. This requirement applies to the branded products listed in the policy (examples include Clindagel 1% topical gel, Amzeeq 4% topical foam, Acanya 1.2%/2.5% gel, BenzaClin 1%/5% gel, Neuac Kit, Onexton 1.2%/3.75% gel, and other clindamycin/benzoyl peroxide formulations) and must be obtained before coverage will be provided.
- Prior authorization applies when coverage is available and medical necessity criteria are met.
- Receipt of sample product does not satisfy criteria or substitute for prior authorization.
Follow step‑therapy trials (trial and failure/intolerance to specified alternatives)
Step therapy is enforced: most branded products require documented trial and failure, intolerance, or contraindication to specified alternative topical agents before the branded product is covered. Required alternatives vary by product (for example, trials of bioequivalent generic clindamycin gel, topical dapsone 5% gel, topical erythromycin products, or benzoyl peroxide combinations as specified in each product’s criteria).
- Amzeeq — failure, contraindication, or intolerance to BOTH: one topical clindamycin-containing product AND one topical erythromycin-containing product.
- Acanya/BenzaClin/Onexton/Neuac — trials of specified bioequivalent generic clindamycin/benzoyl peroxide gels or concurrent benzoyl peroxide with topical clindamycin and other listed alternatives as detailed per product criteria.
Provide detailed clinical documentation of prior trials, contraindications, or intolerance
Document the specific prior trials, contraindications, or intolerances required by the product‑specific criteria to support authorization and continuation. Continuation (reauthorization) also requires documentation of beneficial response. Note that receipt of a sample does not satisfy trial requirements.
- Include dates, product names, doses/formulations, duration of each prior trial, and clinical reason for discontinuation (failure, intolerance, or contraindication).
- For products requiring a trial of a bioequivalent generic, document inability to take the generic due to a formulation difference in inactive ingredients that would cause a significant allergy or serious adverse reaction.
- For reauthorization, provide documentation of beneficial response to the covered product.
Submit claims with appropriate covered diagnosis/procedure codes or risk denial
Use the appropriate covered diagnosis and procedure codes when submitting claims; claims submitted without covered code(s) under this Coverage Policy will be denied as not covered. When billing, providers must use the most appropriate codes as of the submission date.
- Claims lacking covered diagnosis or procedure codes under this policy will be denied as not covered.
- Ensure dosage, frequency, duration, and site of care are reasonable and supported by documentation when submitting requests.
Definitions and Product Summaries
Background
Topical non‑retinoid agents include antibiotics and antimicrobial combinations such as clindamycin, topical minocycline foam, and benzoyl peroxide combinations, as well as sulfacetamide/sulfur formulations. These products are primarily indicated for acne vulgaris, and some combinations are also used for conditions such as rosacea and seborrheic dermatitis. Formulation choice (e.g., gel, foam, cream, lotion) is often guided by skin type and tolerability; clinicians commonly combine topical agents (for example, a retinoid with benzoyl peroxide) to enhance efficacy while minimizing resistance concerns associated with topical antibiotics.
Revision History and Policy Changes
No criteria changes noted; policy effective date updated to 08/15/2026.
No criteria changes noted during review on 07/30/2026.
Employer Preferred Product table: removed Onexton preferred product requirements (listed 07/02/2025; effective 09/01/2025).
Removed Dapsone products (Aczone) medical necessity criteria from this policy (listed 09/19/2024; effective 01/01/2025).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.